WHO Prioritizes Regeneron’s Maftivimab for Bundibugyo Ebola Trials
REGN•WHO’s Therapeutics Advisory Group prioritized Regeneron’s maftivimab for clinical trials against Bundibugyo ebolavirus after in vitro studies demonstrated broad neutralizing activity. Regeneron has deployed Inmazeb stockpiles to the DRC and is preparing standalone maftivimab supplies for imminent outbreak research.
1. WHO Prioritization for Maftivimab
The WHO’s Therapeutics Advisory Group has prioritized Regeneron’s maftivimab for clinical trials against Bundibugyo ebolavirus after in vitro studies demonstrated broad neutralization across multiple Ebola species.
2. Maftivimab In Vitro Activity and Trial Plans
Laboratory evaluations confirmed maftivimab as the most potent neutralizing antibody component of Inmazeb, prompting plans for standalone monotherapy trials in coordination with health authorities in the Democratic Republic of the Congo and Uganda.
3. Inmazeb Stockpile and Emergency Deployment
Regeneron has deployed Inmazeb stockpiles to the DRC and provided hundreds of doses under compassionate use since 2018, while preparing dedicated maftivimab supplies for rapid initiation of outbreak research.
4. Regeneron’s Global Health Response
Building on its FDA-approved triple-antibody cocktail, Regeneron is collaborating with federal agencies and local partners to support global Ebola preparedness and facilitate effective clinical evaluation.
